BPL Therapeutics

BPL Therapeutics is the therapeutics and manufacturing arm historically associated with Bio Products Laboratory, a UK plasma-derived medicines company that was combined with Kedrion in 2022. The business develops, manufactures, and commercializes plasma-derived protein therapies for rare diseases and critical care, with core product categories in coagulation factors, immunoglobulins, hyperimmune products, and albumin. Its best-known rare disease product is Coagadex, a plasma-derived coagulation factor X concentrate for hereditary factor X deficiency. The organization has operated from Elstree, United Kingdom, with U.S. commercial operations in Durham, North Carolina and an upstream plasma collection business in the United States. Today BPL Therapeutics appears to function as a brand/division within the broader Kedrion platform rather than as an independent standalone company.